5 results on '"Angel Alonso Sanchez"'
Number of results to display per page
Search Results
2. HARMONI: first light spectroscopy for the ELT: instrument final design and quantitative performance predictions
- Author
-
Sofia Dimoudi, Jorge Chao Ortiz, Alexandre Jeanneau, Joel Vernet, Eric Daguisé, Adrien Hours, William Bon, Laurence Routledge, Ian Tosh, Eric Stadler, Ana Monreal, Kearn Grisdale, Ruben Sanchez-Janssen, Luis Fernando Rodriguez-Ramos, Jim Lynn, Alvaro Menduina, Angel Alonso Sanchez, Javier Piqueras López, Sylvain Guieu, Aurélien Jarno, Lazar Staykov, Teodora Viera, Joshua Hopgood, Chris Miller, David King, Vanessa Ferraro-Wood, Edgard Renault, Sandi Wilson, Matteo Accardo, James Carruthers, Alberto Estrada Piqueras, Matthieu Guibert, Cyril Petit, Angus Gallie, Zoltan Hubert, William Cochrane, Patricia Fernández Izquierdo, Kenny Campbell, Afrodisio Vega Moreno, Thierry Fusco, David Gooding, Patrice Sanchez, Madeline Close, Mark Swinbank, Jose Luis Rasilla, Arthur Vigan, Andrea Melissa Hidalgo, Romain Fétick, Miguel Pereira Santaella, Adam Lowe, Hermine Schnetler, Michael Meyer, E. Joven, Jean-Luc Gach, Yves Magnard, Josh Anderson, Benoit Neichel, Andy Born, José Peñate Castro, Simon L. Morris, José Linares, Kayhan Gültekin, Nicholas Bouché, Naomi Dobson, Chris Evans, John Capone, Jean-François Sauvage, Yolanda Martín Hernando, Miguel A. Cagigas, Jean-Emmanuel Migniau, Lynn Ritchie, Noah Schwartz, Didier Boudon, Ian Bryson, Alejandro Crespo, Neil Campbell, Jose Miguel Delgado, Alexis Carlotti, Johan Richard, Benoit Epinat, Matthew J. Townson, Stuart Watt, Charlotte Bond, Monica Valluri, Martin Black, Ellis Elliott, Pascal Vola, Elvio Hernandez Suarez, Miriam García García, Magali Loupias, Kacem El-Hadi, Fraser Clarke, John Murray, Matthias Tecza, Patrick Smith, Domingo Avarez Mendez, Leander Mehrgan, Nick Cann, Kjetil Dohlen, Frédéric Gonté, Karen Disseau, Lisa Bardou, Michael J. Booth, David Montgomery, Dave Melotte, Laurent Jocou, Nicola Vedrenne, Florence Laurent, Ana Belén. Fragoso López, Carlos Correia, Tom Louth, William Humphreys, Felipe Pedreros, David Henry, James Kariuki, David Le Mignant, Patrick Rabou, Elizabeth George, Olivier Beltramo-Martin, Sebastian Egner, Olivier Groussin, C. B. Lim, S. Rousseau, Myriam Rodrigues, Jean-Jacques Correia, Martyn Wells, Marc Llored, Thierry Contini, Ralf Conzelmann, Thibaut Moulin, Tea Seitis, Taha Bagci, Joel Le Merrer, Jeremy Blaizot, Oscar A. Gonzalez, Anne Bonnefoi, A. Remillieux, Diane Chapuis, Tim Morris, Derek Ives, Niranjan Thatte, Dimitra Rigopoulou, Roy Preece, Elodie Choquet, Laure Piqueras, Maria Begoña. Garcia-Lorenzo, Fabrice Pancher, Alain Delboulbe, Marie Larrieu, Battaglia Giuseppina, William Ceria, Mario Mateo, Michele Cappellari, Celine Peroux, Rishi Deshmukh, Arlette Pécontal-Rousset, Santiago Arribas, Roberto López, Joel Harman, Norman O'Malley, E. Mueller, Issa Jaafar, Zeynep Ozer, Kieran O'Brien, Anne Costille, Franck Ducret, Yan Fantei-Caujolle, Eddy Younger, Ian Lewis, Marc Dubbledam, Rafael Rebolo, Munadi Ahmad, Evencio Mediavilla, Daniel Lecron, DOTA, ONERA, Université Paris Saclay [Châtillon], and ONERA-Université Paris-Saclay
- Subjects
[SDU.ASTR]Sciences of the Universe [physics]/Astrophysics [astro-ph] ,Computer science ,Integration testing ,First light ,01 natural sciences ,010309 optics ,Integral field spectrograph ,0103 physical sciences ,Systems engineering ,Milestone (project management) ,Extremely Large Telescope ,Adaptive optics ,010303 astronomy & astrophysics ,ComputingMilieux_MISCELLANEOUS ,Design review - Abstract
HARMONI is the adaptive optics assisted, near-infrared and visible light integral field spectrograph for the Extremely Large Telescope (ELT). A first light instrument, it provides the work-horse spectroscopic capability for the ELT. As the project approaches its Final Design Review milestone, the design of the instrument is being finalized, and the plans for assembly, integration and testing are being detailed. We present an overview of the instrument's capabilities from a user perspective, provide a summary of the instrument's design, including plans for operations and calibrations, and provide a brief glimpse of the predicted performance for a specific observing scenario. The paper also provides some details of the consortium composition and its evolution since the project commenced in 2015.
- Published
- 2020
- Full Text
- View/download PDF
3. The Manchester International Consensus Group Recommendations for the Management of Gynecological Cancers in Lynch Syndrome
- Author
-
Emma J. Crosbie, Neil A.J. Ryan, Mark J. Arends, Tjalling Bosse, John Burn, Joanna M. Cornes, Robin Crawford, Diana Eccles, Ian M. Frayling, Sadaf Ghaem-Maghami, Heather Hampel, Noah D. Kauff, Henry C. Kitchener, Sarah J. Kitson, Ranjit Manchanda, Raymond F.T. McMahon, Kevin J. Monahan, Usha Menon, Pål Møller, Gabriela Möslein, Adam Rosenthal, Peter Sasieni, Mourad W. Seif, Naveena Singh, Pauline Skarrott, Tristan M. Snowsill, Robert Steele, Marc Tischkowitz, Angel Alonso Sanchez, James Bolton, David Church, Karen Donnelly, Richard J. Edmondson, D. Gareth Evans, Paula Gollop, Selina Goodman, Shirley Hodgson, Fiona Lalloo, Anne Lowry, Rhona J. McVey, Tracie Miles, Gabriela Moeslein, Pal Moller, Astrid Stormoken, Helen Stringfellow, Andrew Wallace, Luciya Whyte, Nafisa Wilkinson, Godfrey Wilson, Jo Wilson, and Nick Wood
- Subjects
MICROSATELLITE INSTABILITY ,0302 clinical medicine ,Colorectal Neoplasms, Hereditary Nonpolyposis/epidemiology ,Endometrial Neoplasms/epidemiology ,Mass Screening ,MUTATION ,Genetics (clinical) ,Early Detection of Cancer ,Ovarian Neoplasms ,Genetics & Heredity ,RISK ,0303 health sciences ,Manchester Cancer Research Centre ,CLINICAL-CRITERIA ,WOMEN ,NONPOLYPOSIS COLORECTAL-CANCER ,TUMORS ,Lynch syndrome ,3. Good health ,Europe ,030220 oncology & carcinogenesis ,endometrial cancer ,surveillance ,Female ,Ovarian Neoplasms/epidemiology ,Life Sciences & Biomedicine ,guidance ,medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,Consensus ,Genital Neoplasms, Female ,QUALITY-ASSURANCE ,Best practice ,OVARIAN-CANCER ,Unmet needs ,03 medical and health sciences ,Special Article ,medicine ,Humans ,030304 developmental biology ,0604 Genetics ,Science & Technology ,business.industry ,Endometrial cancer ,ResearchInstitutes_Networks_Beacons/mcrc ,screening ,nutritional and metabolic diseases ,1103 Clinical Sciences ,medicine.disease ,Gynecological cancer ,Colorectal Neoplasms, Hereditary Nonpolyposis ,digestive system diseases ,Endometrial Neoplasms ,Family medicine ,Expert opinion ,Manchester International Consensus Group ,North America ,Genital Neoplasms, Female/epidemiology ,business - Abstract
Purpose\ud \ud There are no internationally agreed upon clinical guidelines as to which women with gynecological cancer would benefit from Lynch syndrome screening or how best to manage the risk of gynecological cancer in women with Lynch syndrome. The Manchester International Consensus Group was convened in April 2017 to address this unmet need. The aim of the Group was to develop clear and comprehensive clinical guidance regarding the management of the gynecological sequelae of Lynch syndrome based on existing evidence and expert opinion from medical professionals and patients.\ud \ud Methods\ud \ud Stakeholders from Europe and North America worked together over a two-day workshop to achieve consensus on best practice.\ud \ud Results\ud \ud Guidance was developed in four key areas: (1) whether women with gynecological cancer should be screened for Lynch syndrome and (2) how this should be done, (3) whether there was a role for gynecological surveillance in women at risk of Lynch syndrome, and (4) what preventive measures should be recommended for women with Lynch syndrome to reduce their risk of gynecological cancer.\ud \ud Conclusion\ud \ud This document provides comprehensive clinical guidance that can be referenced by both patients and clinicians so that women with Lynch syndrome can expect and receive appropriate standards of care.
- Published
- 2019
- Full Text
- View/download PDF
4. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain)
- Author
-
Ainara Ruiz de Sabando, Edurne Urrutia Lafuente, Fermín García-Amigot, Angel Alonso Sánchez, Lourdes Morales Garofalo, Sira Moreno, Eva Ardanaz, and Maria A. Ramos-Arroyo
- Subjects
Hereditary breast and ovarian cancer (HBOC) ,BRCA1/2 ,Recurrent mutations ,Demographics ,Sporadic breast and ovarian cancer ,Laterality and stage of tumors ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Genetic testing for BRCA1/2 genes is widely used as a strategy to reduce incidence and morbidity of hereditary breast and ovarian cancer (HBOC). The purpose of this study is to analyse the demographic and molecular characteristics of BRCA germline mutations in Navarra, Spain, and to investigate the clinical profile of hereditary and sporadic breast cancer (BC) and ovarian cancer (OC) in the Community. Methods The study includes 1246 individuals assessed for BRCA1/2 genetic testing in Navarra, during 2000–2016, and a cohort of BC (n = 4384) and OC (n = 561) from the population-based Navarra Cancer Registry. Distribution and molecular characteristics of BRCA1/2 mutations, as well as, comparative analysis of the clinical course, pathologic features and overall survival (OS) of patients in different risk groups were investigated. Results BRCA mutation detection rate was 16%, with higher proportion (63%) of BRCA2 families. Nineteen per cent of mutations were recurrent, one of which, BRCA2 c.6024dupG, showed high association to OC. BRCA carriers had double risk (95% CI = 1.04–4.33) of developing multiple malignancies than low risk families and were diagnosed at a much earlier age (16.6 and 11.7 years difference for BC and OC, respectively) when compared to the general population. For BC, BRCA carriers showed a more advanced histological stage, higher risk of bilateral neoplasms (OR = 4.3; 95% CI = 1.3–11.4, for BRCA2 carriers) and worse OS rate at 5-, 10- and 15- years, than women with sporadic tumors. For OC, over 70% of patients of all risk groups showed advanced stages at diagnosis, with the highest among BRCA1 carriers (91%). Furthermore, they also had higher probability of developing ovarian bilateral tumors (OR = 7.8, 95% CI = 1.7–55.7, for BRCA1 carriers) than the general population. Five-year OS rate was worse among women with sporadic OC than BRCA carriers, but it levelled out over the 15-year period. Conclusions In addition to national similarities in the HBOC-BRCA1/2 associated mutational spectrum, we identified a recurrent BRCA2 pathogenic variant (c.6024dupG), highly associated to OC in Navarra. Carriers of BRCA1/2 mutations showed a more severe BC and OC phenotype and had a worse overall prognosis when compared to a large cohort of women with sporadic counterpart tumors.
- Published
- 2019
- Full Text
- View/download PDF
5. Correction to: Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain)
- Author
-
Ainara Ruiz de Sabando, Edurne Urrutia Lafuente, Fermín García-Amigot, Angel Alonso Sánchez, Lourdes Morales Garofalo, Sira Moreno, Eva Ardanaz, and Maria A. Ramos-Arroyo
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Following publication of the original article [1], the authors reported an error in Figure 2, where the color code of the text boxes is reversed. Figure 2-amended shows the correct color association between the text boxes and the different areas in the map: Navarra, neighbouring communities and other Spanish communities.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.